Impact of COVID 19: perspectives from gastroenterology

Shu Wen Tay1,*, MRCP, Kevin Kim Jun Teh1,*, MRCP, Lai Mun Wang2,3, FRCPEd, FRCP, Tiing Leong Ang1,4,5, FRCPEd, FAMS

1Department of Gastroenterology and Hepatology, 2Pathology Section, Department of Laboratory Medicine, Changi General Hospital, 3Pathology ACP, 4Medicine ACP, SingHealth Duke-NUS Academic Medical Centre, 5Yong Loo Lin School of Medicine, National University of Singapore, Singapore
*These authors contributed equally as first authors.

Correspondence: Prof Tiing Leong Ang, Chief and Senior Consultant, Department of Gastroenterology and Hepatology, Changi General Hospital, 2 Simei Street 3, Singapore 529889. ang.tiing.leong@singhealth.com.sg

Singapore Med J 2020, 1–7
https://doi.org/10.11622/smedj.2020051
Published ahead of print: 13 April 2020

Online version can be found at
http://www.smj.org.sg/online-first
OVERVIEW

A novel human coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]), resulting in an outbreak of respiratory disease (COVID-19), was first reported in Wuhan, China, in December 2019.\(^{(1)}\) COVID-19 was declared a pandemic by World Health Organization on 11 March 2020. By the end of March 2020, almost a million people had been afflicted.\(^{(2)}\) This reflects the ease of transmission amid global interconnectivity. Most infected patients have mild disease. When severe disease with viral pneumonia occurs, it may rapidly progress to acute respiratory distress syndrome, resulting in respiratory failure and death. Current management strategies focus on public health and infection control measures to contain the disease, and respiratory support and treatment of severe cases. SARS-CoV-2 infection is of relevance to the field of gastroenterology due to gastrointestinal (GI) involvement and manifestations,\(^{(3)}\) its impact on vulnerable patients,\(^{(4)}\) and the risk of transmission during GI endoscopy procedures.\(^{(5)}\)

GASTROINTESTINAL MANIFESTATIONS

Human coronaviruses are known to cause both respiratory and GI symptoms.\(^{(6)}\) Entry of coronaviruses into host cells is mediated by surface spike glycoproteins, which bind to angiotensin converting enzyme 2 (ACE2) receptors on human host cells.\(^{(7)}\) Immunohistochemistry studies have revealed that ACE2 receptors are abundantly present in lung alveolar type 2 cells and the enterocytes of the small intestine, with staining seen confined to the brush border in the latter.\(^{(8)}\) Infection of ACE2 receptors that express absorptive enterocytes can result in diarrhoea. SARS-CoV-2 RNA has been detected in stool samples, raising the possibility of faecal-oral transmission.\(^{(9)}\) Hence, although direct droplet transmission is probably the most important route of transmission, faecal excretion with
environmental and fomite contamination may also contribute to viral transmission. This highlights the importance of good sanitation and proper hand hygiene.

The majority of patients that are diagnosed with COVID-19 present with a combination of fever and respiratory symptoms. However, GI symptoms do occur in some and may cause diagnostic confusion. The actual prevalence rates of reported GI symptoms differ across published studies, and this may reflect true differences in the studied populations, the phase of the disease being captured or study design limitations, as these are all retrospective observational studies. The diagnosis of GI symptoms arising from COVID-19 infection will be obvious in patients with epidemiological risk factors who present first with respiratory symptoms with or without fever within 14 days of exposure to the disease. A multicentre study with 1,099 patients from China reported a median incubation period of 4 (interquartile range 2–7) days. With the onset of local transmission, where there is an absence of exposure to known clusters, GI symptoms may pose a diagnostic challenge. Fortunately, current epidemiological data suggest that fever and respiratory symptoms generally predate GI symptoms and are the dominant symptoms. Thus, we should look out for these features during systemic review. Table I summarises the occurrence of GI symptoms in published studies, and these GI symptoms are contextualised in terms of the predominant symptoms of fever and respiratory symptoms. Recognising these GI symptoms as being part of the acute infection can help to decrease unnecessary GI investigations during active disease. The studies by Chen et al, Wang et al and Guan et al reported the occurrence of GI symptoms at admission to hospital, but did not explore the temporal relationship between the onset of GI symptoms and fever/respiratory symptoms. The study by Fang et al specifically examined GI manifestations, which developed at 1–10 days after disease onset. Reported GI symptoms included nausea (29.4%, 59/201), vomiting (15.9%, 32/201), abdominal pain (6.0%, 12/201)
and diarrhoea (49.5%, 146/295). After the exclusion of possible drug-related diarrhoea, the incidence of diarrhoea remained high at 22.2%.(13)

Table I. Gastrointestinal symptoms as compared to fever and respiratory symptoms in COVID-19 patients in the published literature.

<table>
<thead>
<tr>
<th>Clinical symptom</th>
<th>Chen et al(10) (n = 99)</th>
<th>Wang et al(11) (n = 138)</th>
<th>Guan et al(12) (n = 1,099)</th>
<th>Fang et al(13) (n = 305)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever</td>
<td>83.0%</td>
<td>98.6%</td>
<td>43.8%*; 8.7%†</td>
<td>81.1%</td>
</tr>
<tr>
<td>Cough</td>
<td>82.0%</td>
<td>59.4%</td>
<td>67.8%</td>
<td>39.3%</td>
</tr>
<tr>
<td>Dyspnoea</td>
<td>31.0%</td>
<td>31.2%</td>
<td>18.7%</td>
<td>Not reported</td>
</tr>
<tr>
<td>Vomiting</td>
<td>1.0%</td>
<td>3.6%</td>
<td>5%</td>
<td>15.9%</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>2.0%</td>
<td>10.1%</td>
<td>3.8%</td>
<td>49.5%</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>Not reported</td>
<td>2.2%</td>
<td>Not reported</td>
<td>6.0%</td>
</tr>
</tbody>
</table>

*On admission. †During course of hospitalisation.

Liver function test (LFT) abnormalities have been reported. These abnormalities may reflect systemic inflammation or adverse effects of medications, or may be the consequence of organ failure. The virus itself does not result in acute hepatitis. Fang et al reported elevations in serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) or bilirubin levels in 39.1% (119/304) of patients at admission. However, those with ALT or AST ≥ 80 U/L accounted for only 7.9% (24/304) and 6.3% (19/304) of the patients, respectively. Only 2.0% (6/304) of patients had elevated serum bilirubin level. The prevalence of LFT abnormalities was significantly higher in the critically ill group compared to the non-critically ill group.(13) Another study suggested that severe LFT abnormalities are due to adverse drug reactions and systemic inflammation in severely ill patients receiving medical treatment.(14) In a report that described autopsy findings, Xu et al noted that while pathological features of ARDS were evident in the lungs, the liver demonstrated only moderate microvascular steatosis with mild lobular and portal activity, which could be either infection-related or due to drug-induced liver injury. Flow cytometry analysis of peripheral blood suggested that over-activation of T cells,
manifested by an increase of Th17 and high cytotoxicity of CD8 T cells, contributed to the severe immune injury.\(^{(15)}\)

**IMPACT ON GASTROENTEROLOGY PRACTICE**

It is unlikely that a patient will present solely with GI symptoms as a manifestation of symptomatic COVID-19 infection. A thorough systemic review during history taking should be performed, as the cardinal symptoms of fever and respiratory symptoms may be overlooked by the patient. As some GI patients have chronic or recurrent GI symptoms such as irritable bowel syndrome and inflammatory bowel disease, the clinician needs to be mindful of the potential interplay of symptoms, with COVID-19-related symptoms being confused with symptomatic relapse of the underlying GI condition, and vice versa. Patients requiring long-term immunosuppression such as those with inflammatory bowel disease and autoimmune hepatitis, as well as patients who are immunocompromised due to chronic disease states such as liver cirrhosis, are a vulnerable group during the current COVID-19 pandemic.\(^{(3)}\) These patients need to be counselled on risk mitigation and avoidance of exposure. Immunosuppression needs to be tailored on an individualised basis. For infected patients with GI symptoms, one needs to recognise the possibility of GI symptoms being part of the disease manifestation and avoid excessive investigations. Noncrucial invasive tests should be deferred till recovery to minimise the risk of disease transmission.

Endoscopy is an intrinsic part of gastroenterology practice. When a country is completely overwhelmed by an outbreak, all elective procedures would cease, and the limited resources left for GI endoscopy would be channelled toward only life-saving emergency therapeutic GI endoscopy procedures. When the outbreak is still contained and if resources permit, it is possible to continue performing routine GI endoscopy procedures that cannot be deferred for too long for uninfected patients. There is a risk of transmission of infection to
healthcare professionals (HCP) during endoscopy from undiagnosed or pre-symptomatic patients.\(^{(16)}\) This issue has been addressed by the Chapter of Gastroenterologists, Academy of Medicine, Singapore, in a recently published guideline.\(^{(17)}\) In essence, both upper and lower GI endoscopy procedures may result in transmission of infection. Upper endoscopy procedures are considered aerosol-generating procedures. SARS-CoV-2 can be detected in the faeces of infected patients, raising the concern of a faecal-oral route of transmission.\(^{(9)}\) Thus, precautions taken during the performance of colonoscopy should be the same as that for upper endoscopy.

It is important to perform patient screening and risk stratification before listing a patient for an elective procedure. The aim is to identify patients who may potentially be infected or are at risk of being infected, and reschedule their elective endoscopy to a later date when it is clearer that they are not infected. For patients with confirmed or suspected COVID-19 infection, only emergency GI endoscopic procedures that have an immediate impact on management should be performed. As procedures could conceivably be performed in asymptomatic undiagnosed patients due to disease spread in the community and an endoscopy list generally consists of a mix of both upper and lower endoscopy cases, it is recommended that enhanced personal protective equipment (PPE) be used for all GI endoscopy procedures during the current COVID-19 pandemic. This enhanced PPE consists of an N95 face mask, eye protection with goggles or a face shield, an operating theatre cap or hairnet, a water-resistant gown, and gloves. Hand hygiene must be practised when PPE is worn and removed. For confirmed or suspected cases of COVID-19 infection needing emergency GI endoscopy procedures, the use of powered air-purifying respirators (if available), in addition to enhanced PPE, provides an additional safety barrier and should be strongly considered. There must be strict adherence to infection prevention and control measures such as endoscope reprocessing and environmental decontamination within the endoscopy room.
REFERENCES


